Posted in Pharmaceutical Marketing, Social Marketing, Social Media, Technology on Dec 16th, 2009
While social media is currently all the rage, it would be folly for us to make this technology our sole focus. This is because a range of new technologies are rapidly growing in mindshare and uptake. In an effort to prevent health marketers from being blindsided by the next leap in marketing technology, we have [...]
Posted in Data First, FDA, Online Health Search, Pharmaceutical Marketing, Public Health on Nov 4th, 2009
To really understand online health searchers, you have to observe them in the wild.
Many of the studies focusing on this group examine their historical search activity. For example, the Pew Internet & American Life Project has reported that “61% of American adults have looked online for health information.” Manhattan Research recently found that 35% of [...]
Posted in Case Studies, Pharmaceutical Marketing, Social Media on Nov 2nd, 2009
This morning I received a tweet exhorting me to learn about Low Dose Naltrexone (LDN) for autoimmune diseases. (Naltrexone, by the way, is approved by the FDA only to treat alcoholism.) Within a few clicks, I found claims that LDN would be a good drug to take for dozens of conditions: everything from neuroblastoma to [...]
Posted in Collaboration, Marketing Strategy, Pharmaceutical Marketing, Social Media on Oct 20th, 2009
Non-Pharma Marketers Please Note: While this post focuses on pharmaceutical marketing, I strongly believe it can benefit health marketers outside of drug firms. The goal of the Path of the Blue Eye project is to expose you to helpful information from other industry segments. Open yourself to ideas from outside of your industry silo and [...]
Posted in Health Marketing, Pharmaceutical Marketing, Social Media on Sep 21st, 2009
Early last weekend, the news broke that the FDA is holding a public hearing to help it adapt its regulatory posture to account for the special characteristics of social and Web 2.0 technologies. Specifically the FDA states that it is:
“[E]valuating how the statutory provisions, regulations, and policies concerning advertising and promotional labeling should be applied [...]
